22nd International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

第22届艾滋病毒合并症和药物不良反应国际研讨会

• 批准号: 10082909
• 负责人: TODD T BROWN
• 金额: $ 4.3万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-24 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10082909
• 关键词: Adverse effects; Age; Cardiovascular Diseases; Cause of Death; Chronic; Chronic Disease; Clinical; Clinical Management; Collaborations; Committee Members; Communities; Disease; Educational workshop; Endocrinologist; Etiology; Europe; Feedback; Fostering; Goals; HIV; HIV Infections; Home environment; Inflammation; International; International AIDS; Internet; Liver diseases; Longevity; Mentors; Metabolic Bone Diseases; Metabolism; Molecular; New York; New York City; Obesity; Opportunistic Infections; Oral; Paper; Pathogenesis; Play; Research; Research Personnel; Retroviridae Infections; Risk Factors; Role; Scholarship; Sleep; Societies; Stroke; Training Programs; Translational Research; Travel; Ursidae Family; Work; adverse drug reaction; antiretroviral therapy; career development; clinical practice; co-infection; comorbidity; disability; healthspan; improved; low and middle-income countries; meetings; pediatric cardiologist; peer; posters; programs; research clinical testing; skills; success; symposium

With the success of antiretroviral therapy (ART), comorbid diseases are now the leading causes of death and disability in people living with HIV around the globe, including low and middle income countries (LMIC). Large meetings, such as the Conference for Retroviruses and Opportunistic Infections and the International AIDS Society Conference, are important venues for scientific exchange regarding the latest advances in HIV Comorbidity research, but smaller, more intimate formats that emphasize discussion and networking are critical to the career development of HIV Comorbidity investigators. The International Workshop for Comorbidities and Adverse Drug Reactions in HIV, now in its 22nd year, provides <200 delegates with an opportunity to come together to discuss the latest findings and controversies in HIV Comorbidity research in one-room, two-day format. Plenary speakers are either noted experts from outside of HIV research or HIV researchers with expertise in a specific comorbidity. Abstract presentations including 24 15-minute talks and a poster session provide ample opportunity for researchers to present and get feedback on their latest work. With this R13, we propose to enhance the 22nd Workshop (September 12th/13th in New York) with the following aims: 1) to provide a forum for the latest HIV Comorbidity research in LMIC by offering travel scholarships to LMIC investigators, supporting an internationally-recognized expert in non-communicable diseases in LMIC as a plenary speaker, and liaising with international training programs, 2) to support early-stage investigators with a scholarship program and a research skill building workshop, and guided poster tour, 3) to increase the impact of the Workshop through the webcast of plenary and abstract presentations. By providing a “scientific home” to an increasing number of HIV Comorbidity investigators from around the world, we hope to catalyze future research efforts in HIV Comorbidities and facilitate the translation of research findings into clinical strategies that can improve the lifespan and health span of PLWH.

随着抗逆转录病毒疗法(Art)的成功，共病现在是主要原因。 全球艾滋病毒携带者的死亡和残疾情况，包括中低位 收入国家(LMIC)。大型会议，如逆转录病毒会议和 机会性感染和国际艾滋病协会会议是重要的场所 就艾滋病毒共病研究的最新进展进行科学交流，但规模较小， 更亲密的形式，强调讨论和网络，对职业生涯至关重要 艾滋病毒共病调查员的发展。合并症国际研讨会 艾滋病毒的药物不良反应，现已进入第22个年头，为200名代表提供了 有机会聚在一起讨论艾滋病毒共病的最新发现和争议 以一间房、两天的形式进行研究。全体演讲者要么是来自外部的知名专家 艾滋病毒研究人员或在特定共病方面具有专业知识的艾滋病毒研究人员。摘要 包括24个15分钟的演讲和海报会议在内的演讲提供了充足的机会 研究人员展示并获得对他们最新工作的反馈。对于这款R13，我们建议 加强第22期讲习班(9月12日/13日在纽约举行)，目标如下：1) 通过提供旅行奖学金，为LMIC最新的艾滋病毒共病研究提供论坛 给LMIC调查人员，支持一位国际公认的非传染性专家 作为LMIC的全体演讲者，并与国际培训方案联系，2) 通过奖学金计划和研究技能培养支持早期调查人员 研讨会和有导游的海报之旅，3)通过 全体会议和抽象报告的网络直播。通过为日益增长的生物多样性提供“科学家园” 来自世界各地的艾滋病毒共病研究人员的数量，我们希望催化未来 在艾滋病毒合并症方面的研究努力，并促进将研究成果转化为 可以提高PLWH的寿命和健康跨度的临床策略。